Randomized trial of 3 maintenance regimens (TAC/SRL vs. TAC/MMF vs. CSA/SRL) with low-dose corticosteroids in primary kidney transplantation: 18-year results
| Autor: | Linda Chen, Giselle Guerra, Mariella Ortigosa-Goggins, George W. Burke, Gaetano Ciancio, David Roth, Jeffrey J. Gaynor, Warren Kupin, Adela Mattiazzi, Lissett Moni |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Graft Rejection
medicine.medical_specialty medicine.medical_treatment Urology Renal function Tacrolimus law.invention Daclizumab Randomized controlled trial law Adrenal Cortex Hormones Statistical significance Medicine Humans Child Kidney transplantation Sirolimus Transplantation business.industry Immunosuppression Middle Aged Mycophenolic Acid medicine.disease Kidney Transplantation Discontinuation Cyclosporine Drug Therapy Combination business Immunosuppressive Agents medicine.drug |
| Zdroj: | Clinical transplantationREFERENCES. 34(12) |
| ISSN: | 1399-0012 |
| Popis: | A randomized trial of 150 primary kidney transplant recipients, initiated in May 2000, compared tacrolimus (TAC)/sirolimus (SRL) vs. TAC/mycophenolate mofetil (MMF) vs. cyclosporine microemulsion (CSA)/SRL (N = 50/group). All patients received daclizumab induction and maintenance corticosteroids. With current median follow-up of 18 years post-transplant, biopsy-proven acute rejection (BPAR) occurred less often in TAC/MMF (26% (13/50)), vs. the TAC/SRL (36% (18/50)) and CSA/SRL (34% (17/50)) arms combined (p = .23), with statistical significance favoring TAC/MMF (p = .05) after controlling for the multivariable (Cox model) effects of recipient age, recipient race/ethnicity, and donor age. First BPAR rate was clearly more favorable for TAC/MMF after stratifying patients by having 0-1 (N = 72) vs. 2-3 (N = 78) unfavorable baseline characteristics (recipient age |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |